NASDAQ · CRE

Cre8 Enterprise Limited

$2.59 +$0.05 (+1.97%) 1D After hours

Key Metrics

$5.12M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow $1.39M
Beta · 1Y 0.08
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 4
    The stock moved +52.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4
  • Apr 13
    From its Mar 6 high, the share price fell 53%.

    Peak close $4.53 on Mar 6; trough close $2.13 on Apr 13. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -53%
  • Mar 6
    The stock moved +72.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$5.12M
Enterprise value
Shares outstanding2.0M
52-wk range$0.27 – $7.77
Avg volume · 20D1.1M
Net cash
Book value / share$3.28
ExchangeNASDAQ
About Cre8 Enterprise Limited
IPO dateJul 23, 2025
Employees91

Cre8 Enterprise Ltd, through its subsidiary, is engaged in the provision of integrated financial printing services for listed companies, IPO applicants, and private companies in the finance and capital market in Hong Kong.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF3.68
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio1.57
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.99M

Cash Flow · TTM

Operating CF $1.48M
Capex −$92.16K
Free cash flow $1.39M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings